2 completed, 1 suspended, 1 terminated, 1 unknown. 5 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 2, Suspended 1, Terminated 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow HER-2 Gene Amplification: new trials by email Literature Review of HER-2 Gene Amplification trials Research Report on HER-2 Gene Amplification
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors ORM-5029 - HER2-positive Breast Cancer, HER-2 Protein Overexpression | Phase 1 | Terminated | Orum Therapeutics USA, Inc. | 25 | 2022-10-03 | 2025-07-04 |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors CT-0508, Pembrolizumab - HER2-positive, Adenocarcinoma | Phase 1 | Unknown | Carisma Therapeutics Inc | 48 | 2021-02-02 | 2024-12-18 |
| Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors chimeric antigen receptor (CAR) T cell therapy - HER-2 Gene Amplification, HER2-positive Gastric Cancer | Phase 1 | Suspended | Bellicum Pharmaceuticals | 220 | 2020-12-07 | 2023-04-20 |
| Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene A166 - HER2-positive Breast Cancer, HER2 Gene Mutation | Phase 1 / Phase 2 | Completed | Klus Pharma Inc. | 49 | 2018-07-16 | 2023-08-03 |
| A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer Cisplatin, Capecitabine, Trastuzumab and MM-111, Lapatinib +/- Trastuzumab and MM-111, Paclitaxel, Trastuzumab and MM-111 - HER-2 Gene Amplification | Phase 1 | Completed | Merrimack Pharmaceuticals | 100 | 2011-01-01 | 2015-12-16 |
Breast Neoplasms (3) · Stomach Neoplasms (3) · Bile Duct Neoplasms (2) · Head and Neck Neoplasms (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Prostatic Neoplasms (2) · Urinary Bladder Neoplasms (2) · Adenocarcinoma (1) · Biliary Tract Neoplasms (1) · Carcinoma, Ductal (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Mucoepidermoid (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1)
Breast Diseases (3) · Digestive System Diseases (3) · Digestive System Neoplasms (3) · Gastrointestinal Diseases (3) · Gastrointestinal Neoplasms (3) · Neoplasms by Site (3) · Skin Diseases (3) · Skin and Connective Tissue Diseases (3) · Stomach Diseases (3) · Adnexal Diseases (2) · Bile Duct Diseases (2) · Biliary Tract Diseases (2) · Carcinoma (2) · Colonic Diseases (2) · Endocrine Gland Neoplasms (2)
Automobiles (1) · Capecitabine (1) · Cisplatin (1) · Docetaxel (1) · Lapatinib (1) · MM-111 (1) · Paclitaxel (1) · Receptors, Chimeric Antigen (1) · Trastuzumab (1) · pembrolizumab (1)
Bellicum Pharmaceuticals (1) · Carisma Therapeutics Inc (1) · Klus Pharma Inc. (1) · Merrimack Pharmaceuticals (1) · Orum Therapeutics USA, Inc. (1)
United States (5)
Jeanett Wetzel (1) · Jordi Rodon Ahnert, MD, PhD (1)